fig6

Figure 6. THZ2 inhibits SOX9 expression in GBM cells. (A) Protein levels of SOX9 following 48-hour treatment with 0.25-0.5 μM THZ2 in four GBM cells (n = 3); (B) mRNA levels of SOX9 following the same treatment (n = 3); (C) Effects of THZ2 and TMZ, alone or in combination, on SOX9 expression in subcutaneous GBM tissue. Scale bars: 20 μM. Data are presented as mean ± SD from three independent experiments (n = 3). ns: No significant; ^**P < 0.01; ^***P < 0.001. Statistical significance was assessed using one-way ANOVA. GBM: Glioblastoma; TMZ: temozolomide; SD: standard deviation; ANOVA: analysis of variance.